SafeRide Health (SRH) is the new provider for all NEMT rides to doctor appointments and pharmacy visits.
Depending on your needs, rides may include wheelchair-lift-equipped vehicles, stretcher vans, minivans, or ambulatory vans. Please let SRH know what type of ride you need when scheduling.
SafeRide Health (SRH) es el nuevo proveedor de todos los servicios de transporte médico que no son de emergencia (NEMT, por sus siglas en inglés) hacia consultas médicas y farmacias.
Según tus necesidades, los servicios de transporte pueden incluir vehículos con elevador para sillas de ruedas, camionetas con camilla, minivans o camionetas ambulatorias. Por favor, informa a SRH qué tipo de transporte necesitas al programar tu traslado.
Effective date for benefit: April 1, 2026 Effective date for Prior Authorization: May 1, 2026
Call to action:Texas Children’s Health Plan (TCHP) would like to inform providers that Papzimeos (zopapogene imadenovec-drba) is a non-replicating adenoviral vector-based immunotherapy indicated for the treatment of adults with recurrent respiratory papillomatosis.
Background: Health and Human Services Commission (HHSC) will add Papzimeos (procedure code J3404) as a Medicaid and CHIP benefit beginning on April 1, 2026, and requires prior authorization for these programs effective May 1, 2026.
How this impacts providers: Authorization requirements
Prior authorization is required for Papzimeos (zopapogene imadenovec-drba).
The prior authorization request for Papzimeos (zopapogene imadenovec-drba) may be approved for 6 months for patients meeting the following requirements:
Patient is 18 years of age or older.
Patient has a confirmed diagnosis of recurrent respiratory papillomatosis (diagnosis code: D14.1).
Patient has documented human papillomavirus (HPV) serotype 6 or 11.
Prescribers must perform a surgical debulking of visible papilloma prior to the initiation of Papzimeos treatment (Day 1) to establish minimal residual disease.
Prescriber attests to remove visible papilloma prior to the third and fourth Papzimeos administration to maintain minimal residual disease during treatment.
Authorization will be approved for no more than one treatment course (i.e., four doses).
Monitoring parameters: Monitor for signs and symptoms of thrombotic events (e.g., shortness of breath, chest pain, leg swelling, persistent abdominal pain, neurological symptoms, including severe or persistent headaches or blurred vision).
Next step for Providers: Providers should share this communication with their staff.
